Prophylactic vaccines for genital human papillomavirus (HPV) infection have been shown to be feasible in animal models, and suitable vaccine material based on virus-like particles can be produced in bulk at reasonable cost. Initiation of phase III clinical trials will follow definition of trial outcome measures through further epidemiological studies, and development of assays of host protective immunity. Vaccines could in principle eliminate HPV-related disease, as the human race is the only natural host for the relevant papillomaviruses (PVs). Therapeutic vaccines for genital HPV infection are also possible, but have not yet been demonstrated as feasible in practice because the choice of vaccine antigens is difficult, the method of their optimal delivery is uncertain, and the nature of the relevant antiviral immunity is unknown. PV species specificity will require trials to be conducted in man, which will slow definition of an ideal vaccine. (Genitourin Med 1996;72:398-403 
3 Study design Because of the problems outlined above, design of studies to demonstrate vaccine efficacy is not self evident. In this section some possible vaccine trials will be outlined to highlight the issues to be resolved.
Prophylactic vaccines-genital warts
Young adults prior to sexual activity can be presumed to comprise a largely HPV6 and HPV1 1 naive population, and will therefore be the target population of efficacy studies. In contrast, by the age 20 years, one in five sexually active women will have HPV DNA in their cervix as judged by PCR DNA testing.2 One in ten will also have had visible genital warts, although males particularly will often not be aware that they have them. 49 Thus, a window of opportunity exists for testing vaccines in adolescents which is lost by age 20, and the need to test vaccines for efficacy in people under 18 years may cause some ethical concerns. A randomised placebo controlled double blind study will be required, probably involving a cohort of pre-college students, male and female. Exclusion of those subjects who give a history of genital warts, with external wart disease on examination, or with known immune compromise or systemic disease will be required. The volunteer process should self select for those who are likely to become sexually active. However, subjects motivated to participate in a vaccine trial may also be motivated to practice safer sex, which may reduce the risk of HPV related warts.
A successful vaccine might aim to prevent 80% of wart disease. Given an incidence of visible warts in the target population of 5% per annum, and a latency period after infection of up to six months during which a vaccine would be unlikely to be successful, an 18 month trial, with warts appearing during the first 6 months regarded as likely to include those that were incubating anyway, would be required. A 50% dropout rate might be expected, and a doubling of the sample estimate will therefore be required: to give a reasonable power, the study would therefore require about 3000 students! 3.2 A vaccine to prevent HPV cervical dysplasia Cervical dysplasia is asymptomatic. For a study to be valid, the disease to be prevented must be the one which current opinion holds must be treated as part of a prevention programme for cervical cancer (LSIL or CIN1 in most countries). The histological appearance of CINI may represent two different processes: LSIL occurring immediately after any HPV or other viral exposure in the cervix as part of a repair process is relatively likely to regress, while LSIL occurring later in the course of HPV1 6 infection is a dysplastic process, and presumably more likely to progress. Reliable diagnosis of CIN requires a biopsy, which is prone to sampling and interpretation error. This error at recruitment will increase the risk that people with prior exposure are incorrectly included in a study.
Reliable data on the natural history of CIN1 cannot become available in countries where discovery of cervical dysplasia on a Papanicolou smear leads to biopsy, and a biopsy showing CIN1 mandates treatment. The study will be limited to women who are already sexually active, and to ensure a reasonable risk for acquisition of new HPV infection, subjects in the study will have to be HPV negative at recruitment and likely to change sexual partners in the next year. Recruitment will therefore be targeted at young unmarried women who have a normal cervix at entry, which tests negative for HPV DNA. The development of HPV 16 DNA + ve CIN 1 between 3 months after vaccination, and the end of the study would be a negative outcome. No HPV 16 + ve CIN 1 over the duration of the study would be a success. Current cohort studies will give us an estimate of the new HPV 16 infection acquisition rate per year in the target population, and thus allow determination of sample size. 4 Therapeutic vaccines For prophylactic PV vaccines, the underlying science is relatively clear, and there is some consensus that a vaccine based on VLPs, with an adjuvant designed to raise antibody to conformational epitopes, will be the basis of the vaccine. For therapeutic papillomavirus vaccines, in contrast, the scientific basis of a vaccine is not so well defined. The 6 months than no intervention at all, if freedom from wart disease is the sought after outcome. However, most destructive or anti-proliferative therapies will help patients who are destined to be clear of visible warts at 6 months without intervention to achieve this outcome sooner, which from the patient's point of view is highly desirable.
A therapeutic vaccine for HPV infection is predicated on the belief that it can do significantly better than current treatment modalities. A 50% better outcome would be clinically useful. Immunotherapy might be given as adjuvant therapy to prevent disease recurrence after ablative therapy, or as a single primary therapy. The former is preferable for early clinical studies because patients know they will receive best available therapy, and the time to primary study end point is shorter. HPV immunotherapy as primary therapy for extensive HPV associated wart disease might subsequently be trialed. As half of subjects will have recurrent disease by 3 months in the placebo group, a recruitment cohort of 300-500 subjects would be necessary for a reasonable power.
T he role of vaccines in the control of STDs: HPV vaccines In conclusion, the prospects for prophylac- 
